文献速递免疫规划卫生政策与健康促进

推进流感疫苗:下一代候选疫苗及其全球健康影响潜力综述

Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.
PubMed 文献 · Vaccine · 2024-10-05

本文综述下一代流感疫苗的临床研发管线,以CIDRAP通用流感疫苗技术景观为主要参考,结合同行评议文献、临床试验记录等公开信息,比较其与现有获批季节性流感疫苗的特征。分析显示研发管线活跃,mRNA疫苗成为主导平台,通用或广谱保护产品结果令人鼓舞但仍处早期,需持续投资并考虑其整合入现有疫苗株选择、生产生态与免疫规划。

要点

  • 下一代流感疫苗临床研发管线活跃,涵盖多种技术路线,多个候选处于后期开发阶段。
  • mRNA疫苗成为主导平台,既包括改进季节性保护的候选,也包括针对其他呼吸道病毒的联合疫苗。
  • 通用或广谱保护产品结果令人鼓舞但仍处早期,需持续投资并考虑整合入现有疫苗株选择与生产体系。

核心结论

  • 通用或广谱保护产品结果令人鼓舞但仍处早期开发,值得资助方持续投资。
  • 多数3期候选为mRNA疫苗且包含联合疫苗,需开始考虑其如何整合入当前全球流感疫苗株选择、生产生态及现有免疫规划。

研究设计与样本

  • 综述:以CIDRAP通用流感疫苗技术景观为主要参考来源,并从同行评议手稿、临床试验记录及公开媒体中提取补充信息,对下一代流感疫苗候选进行识别与特征描述。

主要发现

  • 下一代流感疫苗临床研发管线活跃,采用多种方法应对现有疫苗挑战,多个候选处于后期开发阶段。
  • mRNA疫苗成为主导平台,表现为聚焦改进季节性保护的候选数量以及靶向其他呼吸道病毒的联合疫苗候选。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza vaccines are an essential tool for influenza prevention, control and preparedness. However, demand for them and their programmatic suitability globally is significantly influenced by their variable effectiveness against influenza illness annually, limited duration of protection and need for yearly updating and vaccination. As such, the World Health Organization and major funders, such as the United States National Institute of Allergy and Infectious Diseases and Bill and Melinda Gates Foundation, have strongly encouraged developing influenza vaccines with increased efficacy, breadth and duration of protection. Here, we review the next-generation influenza vaccine pipeline, focusing on products in clinical development, and compare their characteristics to currently approved seasonal influenza vaccines. METHODS: To identify and characterize next-generation influenza vaccine candidates, we conducted a comprehensive literature review, using the CIDRAP Universal Influenza Vaccine Technology Landscape as a primary reference source and extracting additional information from peer-reviewed manuscripts, clinical trial records and other media in the public domain. RESULTS: Our analysis reveals a robust clinical development pipeline for next-generation influenza vaccines, featuring a diversity of approaches to address existing vaccine challenges and several candidates in advanced stages of development. mRNA vaccines emerged as a predominant platform, as evidenced by the number of candidates focused on improved seasonal protection as well as combination vaccine candidates targeting additional respiratory viruses. CONCLUSION: While still early in development, results from universal or broadly protective products are promising and warrant continued investment from funders. As most Phase 3 candidates are mRNA-based and include combination vaccines, it is critical to begin considering how these new products may become integrated into the current global influenza vaccine strain selection and manufacturing ecosystems, and existing immunization programmes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Taaffe J, Ostrowsky JT, Mott J, et al. Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact. Vaccine. 2024. PMID: 39369576. doi:10.1016/j.vaccine.2024.126408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。